Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | ATP6V1B2 | P21281 | 1/20 | 0.56 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.56 |
| ▸ | EDNRA | P25101 | 1/20 | 0.56 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.56 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.54 |
| ▸ | FLT4 | P35916 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
| ▸ | RARB | P10826 | 1/20 | 0.54 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | HPGD | P15428 | 5/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | XBP1 | P17861 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10549064 | 0.89 | KMT2A (0.56) | KMT2ALMNACYP2C9ATP6V1B2TBXA2R | |
| SCHEMBL8138591 | 0.87 | LMNA (0.54) | KMT2ALMNACYP2C9ATP6V1B2TBXA2R | |
| SCHEMBL312827 | 0.86 | KMT2A (0.71) | KMT2ALMNACYP2C9ATP6V1B2TBXA2R | |
| SCHEMBL10552247 | 0.86 | KMT2A (0.79) | KMT2ALMNACYP2C9EPHA2FLT4 | |
| SCHEMBL10824848 | 0.86 | KMT2A (0.49) | KMT2ALMNACYP2C9ATP6V1B2TBXA2R | |
| Hydrochloric Acid SCHEMBL10551298 | 0.86 | KMT2A (0.70) | KMT2ALMNACYP2C9ATP6V1B2TBXA2R | |
| SCHEMBL6780213 | 0.85 | ALDH1A1 (0.60) | KMT2ALMNACYP2C9ALDH1A1KDM4E | |
| SCHEMBL7610001 | 0.85 | EPHA2 (0.77) | KMT2ALMNACYP2C9ATP6V1B2TBXA2R | |
| SCHEMBL7610008 | 0.85 | EPHA2 (0.77) | KMT2ALMNACYP2C9ATP6V1B2TBXA2R | |
| SCHEMBL11026728 | 0.84 | LMNA (0.79) | KMT2ALMNACYP2C9ATP6V1B2TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730154-B1 | RIFAMYCIN DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | CUMBRE IP VENTURES L P (US) | 2012-10-17 | — | — | EP | disclosed |
| US-7247634-B2 | Rifamycin derivatives effective against drug-resistant microbes | CUMBRE PHARMACEUTICALS INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-20050261262-A1 | Rifamycin derivatives effective against drug-resistant microbes | CUMBRE INC. (US) | 2005-11-24 | — | — | US | disclosed |
| US-4851535-A | 2-(5-FLUORONICOTINOYL)ACETIC ACID DERIVATIVES, ANTIBACTERIAL 1-ARYL-1,4-DIHYDRO-4-OXONAPHTHYRIDINES | TOYAMA CHEMICAL CO., LTD. (JP) | 1989-07-25 | — | — | US | disclosed |
| US-4704459-A | VILSMEIER REAGENT | TOYAMA CHEMICAL CO., LTD. (JP) | 1987-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261262-A1 | Rifamycin derivatives effective against drug-resistant microbes | RIF1, MRPL37, AURKAIP1 | KMT2A 3269/4885LMNA 2569/4885CYP2C9 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.